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Abstract
Human cytomegalovirus (HCMV) and human immunodeficiency virus type-1 (HIV-1) infect the female genital tract. A human cervical explant
model was developed to study single and dual infection by these viruses in the genital compartment. An HCMV strain expressing green fluorescent
protein, and two clinical HCMV strains produced peak viral DNA copies at 14 to 21 days post-infection. Peak levels of HIV-1Ba-L p24 antigen
occurred at 7 days post-infection. HIV-1Ba-L appeared to enhance HCMV in co-infected tissues. Singly and dually infected explants produced
increased levels of cytokines IL-6, IL-8, and GRO-α in culture supernatants. Immunohistochemical and flow cytometric analysis showed HCMV
infection of leukocytes with the phenotype CD45+/CD1a+/CD14+/HLA-DR+ but not stromal or endothelial cells. Cells expressing both GFP and
HIV-1 p24 antigen were detected in co-infected tissues. The cervical explants provide an ex vivo human model for examining mechanisms of virus–
virus interaction and pathogenesis in clinically relevant tissue.
© 2007 Elsevier Inc. All rights reserved.Keywords: Human cytomegalovirus; HIV-1; Cervical explant; Female genital tractIntroduction
Human cytomegalovirus (HCMV) infection is widespread as
evidenced by the high HCMV seroprevalence in the adult
population. Most primary infections are mild or asymptomatic;
however, the virus establishes lifelong latency. Primary infec-
tion or reactivation of latent infection can cause serious disease
in patients who are immunocompromised, such as congenitally
infected infants, transplant recipients, and patients co-infected
with HIV-1 (Arcasoy and Kotloff, 1999; Boppana et al., 2001;
Grossi et al., 1995; Jacobson, 1997; Ross et al., 2006).
HCMV may persist or reactivate in specific body compart-
ments such as the lung and gastrointestinal tract, which can act as
long-term reservoirs of infection and provide opportunities for⁎ Corresponding author. Fax: +1 312 942 6787.
E-mail address: nlurain@rush.edu (N.S. Lurain).
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doi:10.1016/j.virol.2007.07.008interaction with co-infecting pathogens (Jacobson, 1998; Long
et al., 1998; Nowzari et al., 2003; Paya et al., 1993; Sinzger et al.,
1995; Tanaka et al., 2006). The female genital tract is a
compartment where co-infection of HCMVand HIV-1 is known
to occur, and several studies have examined the association
between these two viruses at this site. It was reported that HIV-1-
infected women shed HCMV in cervicovaginal secretions and
both viruses were detected in genital secretions, even when
undetectable in the blood (Clarke et al., 1996; Kovacs et al.,
2001; Lurain et al., 2004; Mostad et al., 1999). Therefore, co-
infection provides the potential for virus–virus interaction that
may increase sexual and perinatal transmission of these viruses.
HCMV and HIV-1 are highly species-specific, which limits
both the cell types that support productive virus replication in
vitro and the use of animal models for in vivo studies. Ex vivo
human cervical tissue models were previously reported for the
study of HIV-1 transmission and replication in the female
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et al., 2002; Palacio et al., 1994). In addition, cervical tissue
explants have been used to examine the efficacy of different
inhibitors of HIV-1 infection (Fletcher et al., 2005; Greenhead
et al., 2000; Hu et al., 2004). We report here the development of
a cervical explant model to study HCMV infection and rep-
lication as well as co-infection with HIV-1.
Results
Infection of cervical explants by cell-free HCMV
The first step in developing this model was to determine the
ability of the explants to support HCMV infection and HIV-1
co-infection. The lengthy course of HCMV infection requires
that the tissue remain viable for at least 21 days post-infection
(p.i.). To address this requirement, small ectocervical explants
were cut from each surgical specimen, inoculated with the cell-
free HCMV strain CMVPT30-gfp, and maintained submerged
in culture medium. For co-infection studies, the explants were
inoculated with HIV-1Ba-L 72 h after HCMV inoculation.
CMVPT39-gfp expresses green fluorescent protein (GFP),
which was first detected an average of 7 days p.i., although in
some tissues GFP-positive cells did not appear for 10–14 days.
To follow the progression of HCMVin singly infected and HIV-1
co-infected tissues, GFP-expressing cells were monitored daily
for a total of 21 to 28 days using an inverted fluorescence
microscope. The number of GFP-positive cells was scored from
1+ to 5+ (see Materials and methods). Based on the fluo-
rescence scores, the number of cells expressing GFP steadily
increased from 1+ to 5+ over a period of 1 to 2 weeks indicating
that the infection was spreading among susceptible cells in the
explant. The peak number of GFP-expressing cells occurred
between days 14 and 21 p.i. in both HCMV singly infected and
co-infected explants, and the average score was significantly
higher at day 14 (p=0.04, Wilcoxan signed rank test) for co-
infected than for explants infected with HCMValone (Table 1).
In live tissue, GFP-expression appeared in individual cells
distributed throughout the explant tissue (Fig. 1A) rather than
plaque-like clusters of adjacent cells as seen in cell culture
monolayers. This suggested that infection was not occurring in
epithelial, endothelial, or stromal cells. The infected cells were
large with multiple extensions protruding from the main cell
body (Fig. 1A, small images). There was some evidence of cellTable 1
Scoring of explants for HCMV-infected fluorescent cells at day 14 post-infection
Tissue CMV CMV/HIV-1
Mean scorea Mean score
A 2.2 (nb=15) 2.5 (n=13)
B 3.1 (n=17) 3.5 (n=16)
C 1.8 (n=13) 2.2 (n=14)
D 1.5 (n=22) 2.1 (n=16)
E 2.3 (n=10) 4.0 (n=9)
a Mean score determined from individual explants from 5 different tissue
specimens scored for fluorescence 1+ to 5+ (see Materials and methods).
b n is the number of explants scored for each tissue specimen.death after day 14 as shown by fragmentation of fluorescent
cells, although the majority of GFP-expressing cells remained
morphologically intact. The overall progression of CMVPT30-
gfp infection appeared to be slower than that observed in cell
culture with the number of fluorescent cells increasing up to at
least 14 days p.i.
To monitor tissue viability, the MTT assay was performed at
the time of inoculation and at selected time points p.i. The
absorbance per milligram of tissue tended to decrease after
14 days indicating a decrease in the number of viable cells,
although the absorbance remained higher than the background
level of control wells that did not contain tissue for as long as
28 days p.i. (data not shown).
Infection of cervical explants by HCMV cell-associated clinical
strains
The production of cell-free virions in cell culture by the
recombinant CMVPT30-gfp strain differs phenotypically from
low-passage clinical HCMV strains, which produce only cell-
associated virus in cell culture. Therefore, we tested three
clinical strains, NW23-2, CH-14, and CH-22, to confirm that
they could replicate in the cervical explants. Because there was
no visual means to follow infection, explants infected with the
clinical strains were harvested and frozen at 14 days p.i. based
on the timing of peak GFP expression observed with
CMVPT30-gfp. The explants were then sectioned and stained
directly for the delayed early non-structural protein, p52
(UL44), using a FITC-conjugated mouse monoclonal antibody
(mAb) (Dako Glostrup, Denmark). Cells positive for p52 were
detected throughout the tissue sections (Fig. 1B) demonstrating
the ability of these clinical strains to replicate in explant tissue.
The staining properties of the anti-p52 antibody in individual
cells differed from GFP expression (Fig. 1B, smaller images) in
being more punctuate and less bright.
Quantitation of CMVPT30-gfp and HCMV clinical strains in
cervical explants
To provide a quantitative measure of HCMV replication in
explant tissue, genomic copy numbers of all HCMV strains
were determined by real-time PCR and normalized by tissue
weight. HCMV DNA copy numbers in singly infected explants
varied, typically within the range of 103 to 106 copies per mg of
tissue. Peak copy numbers of HCMVPT30-gfp occurred on
days 14–21 p.i. (Fig. 2A). Variability in HCMV DNA copy
number occurred within the same tissue and among tissues from
different hosts.
Explants inoculated with cells infected with each of the
clinical HCMV strains (CH-14, CH-22, or NW23-3) produced
detectable HCMV DNA copies in tissue and notably also in
supernatant fluid. DNA extracted from both types of samples
was quantitated by real-time PCR. Peak values occurred on days
14–21 p.i. as shown for NW23-3 (Fig. 2B). When samples from
the same tissue specimen were infected with CMVPT30-gfp,
NW23-3, CH-14, and CH-22, the median copy numbers of two
of the three clinical strains (CH-22 and NW23-3) were 0.5–1.5
Fig. 1. Detection of HMCV-infected cells. (A) Large image shows CMVPT30-gfp-infected cells in live tissue (100×). Smaller images show individual cells infected
with CMVPT30-gfp (200×). (B) NW23-3 infection in frozen tissue sections. Large image shows green fluorescence from FITC-conjugated anti-HCMV p52 antibody;
blue fluorescence is DAPI staining of nuclei (100×). Smaller image on left below shows individual infected cells stained with FITC-conjugated anti-HCMV p52
antibody at higher magnification (200×). Smaller image on right shows same cells with overlay of DAPI staining of nuclei. All images taken with SPOT RT KE 7.3
Three Shot Color digital camera using MetaMorph version 6.0 software.
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isolate, CH-14, produced copy numbers similar to CMVPT30-
gfp. These quantitative data confirm that the cervical explants
are permissive for replication of both higher passage cell-free
virus strains and low passage cell-associated HCMV clinical
strains.
Inhibition of CMVPT30-gfp in cervical explants
Additional evidence for HCMV replication in the explants
was provided by the inhibitory activity of the HCMV antiviral
agent, foscarnet. Explants were pretreated with concentrations
of the drug ranging from 50 μM to 800 μM for 72 h followed by
inoculation with 1×105 pfu of CMVPT30-gfp per well. HCMV
DNAwas extracted from tissue samples for quantitation at day
14 p.i. A dose–response inhibitory effect was seen in the tissue,
with concentrations as low as 50 μM inhibiting viral replication
by almost 80% (Fig. 2D). The highest concentration of fos-
carnet (800 μM) inhibited HCMV replication by 98%.
Infection of cervical explants with HIV-1Ba-L
Others have shown that cervical explants are permissive
for HIV-1 infection (Collins et al., 2000; Fletcher et al.,
2005; Greenhead et al., 2000). We confirmed that our stock
of HIV-1Ba-L could infect and replicate in the explants. Proof of
infection was determined by the qualitative detection of HIV-1
DNA at days 7, 14, and 21 p.i. HIV-1 DNA was present in allexplants infected with HIV-1BaL alone, as well as those co-
infected with both CMVPT30-gfp and HIV-1Ba-L (data not
shown).
Quantitative analysis of HIV-1 replication was determined
by p24 antigen ELISA in supernatants collected beginning at
day 3 p.i., after the inoculum had been removed by repeated
washings. The day 3 time point provided the residual inoculum
background for the p24 antigen assay. In HIV-1-infected tissues,
peak p24 antigen levels consistently occurred at day 7 (Fig. 3)
and then declined in supernatants collected at 14 and 21 days
p.i. These data confirm that the HIV-1Ba-L strain is able to infect
and replicate in the cervical explants under the experimental
conditions of our protocol.
Quantitation of HCMV and HIV-1 co-infection
To study the potential interaction of HCMV and HIV-1 in
cervical tissue, we first performed a series of co-infection
studies with CMVPT30-gfp and HIV-1Ba-L. The explants were
inoculated with CMVPT30-gfp for 72 h before inoculation with
HIV-1Ba-L. The order and timing of exposure to the viruses were
determined by preliminary experiments, which had shown that
the highest HCMV loads resulted from inoculation of the tissues
first with HCMV followed by inoculation with HIV-1 (data not
shown). Co-infected explants were harvested for quantitation at
days 7, 14, and 21 p.i. Similar to singly infected explants,
HCMV DNA copy numbers per milligram of tissue in co-
infected explants reached peak levels at days 14 to 21 p.i. In
Fig. 2. Quantitation of HCMV DNA copy numbers in cervical explants by real-time PCR. Note: all data are log scale. (A) CMVPT30-gfp median copy numbers at
three time points p.i. in tissues from 4 different cervical specimens. (B) NW23-3 median copy numbers at three time points p.i. in tissue supernatants from 4 different
cervical specimens. (C) Comparison of DNA copies from infection of tissue explants from the same specimen with CMVPT30-gfp (solid bars), NW23-3 (diagonal
bars), CH-22 (horizontal bars), and CH-14 (cross-hatch bars) at peak time point, day 14 p.i. (D) Inhibition of CMVPT30-gfp replication by foscarnet in explant tissue at
day 14 post-infection.
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HCMV copy values were greater in co-infected explants than in
those infected with HCMV alone. Figs. 4A–C show theFig. 3. Quantitation of HIV-1Ba-L by p24 antigen ELISA. Each line shows
median results at each time point p.i. for a different host tissue.results of three of these experiments. Note that the HCMV
copy numbers are log scale. For the tissue shown in Fig. 4C, the
median values of the HCMV viral loads for HCMV/HIV-1 co-
infection versus HCMV infection alone at day 14 p.i. reached
statistical significance (p=0.004). Although the median HCMV
copy numbers at days 14 and 21 for the tissues shown in Figs.
4A and B were higher for co-infection compared to single
infection, the difference was not statistically significant, be-
cause the range of HCMV copy numbers at each time point was
too variable.
We next performed similar co-infection studies using HCMV
clinical strains CH-22 and CH-14. The results are shown in
Figs. 4D and E, respectively. Again, the median values for
HCMV genomic copy numbers were greater for co-infected
explants than those singly infected with HCMV. However, the
HCMV DNA copy number differences between co-infected and
singly infected tissues did not reach statistical significance.
HIV-1 p24 antigen values for both single and dual infection
peaked consistently at day 7 (Fig. 4F). Although the median p24
antigen levels were always higher for co-infected explants at
days 14 and 21 compared to those infected with HIV-1 alone,
this difference was not statistically significant.
Fig. 4. Quantitation of HCMV and HIV-1Ba-L co-infection. Graphs in panels A–E are offset at each time point to show bars for interquartile range (25th to 75th percentile). (A–C) CMVPT30-gfp co-infection with
HIV-1Ba-L. Dotted line, CMVPT30-gfp DNA copies in single infection; solid line, CMVPT30-gfp DNA copies in co-infection with HIV-1. Only day 14 difference between single and co-infection in panel C is
statistically significant (p=0.004, Wilcoxan Rank sum test). (D) CH-22 DNA copies in single infection (dotted line) and co-infection with HIV-1Ba-L (solid line); (E) CH-14 single infection (dotted line) and HIV-1
co-infection (solid line). (F) Results of 3 experiments showing HIV-1Ba-L p24 pg/ml determined by ELISA in singly infected tissues (dotted line) and tissues co-infected with CMVPT30-gfp (solid line).
Differences between p24 antigen pg/ml in single and dual infection at days 14 and 21 p.i. are not statistically significant by the Wilcoxan rank sum test.
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Fig. 6. Frozen sections of tissue infected with NW23-3 showing co-localization
of anti-CMV p52 and anti-CD68 antibodies on infected cells. (A) Detection of
CMV with FITC-conjugated anti-CMV p52 mAb; (B) Detection of anti-CD68
primary antibody with Alexa Fluor 594-conjugated F(ab′)2 rabbit anti-mouse
secondary antibody; (C) DAPI staining of nuclei; (D) Overlay of all three fluors.
(E) Frozen section of uninfected control tissue showing Langerhans cells stained
with anti-CD1a primary antibody and Alexa Fluor 594-conjugated F(ab′)2 rabbit
60 A.M. Fox-Canale et al. / Virology 369 (2007) 55–68Based on these quantitative analyses, HCMV co-infection
appears to have no effect on HIV-1 replication. The quantitative
co-infection data and the fluorescent cell scores (Table 1)
suggest that HIV-1 may enhance HCMV replication. However,
the results in most cases are not statistically significant, because
of the intra-tissue variability. These experiments were con-
ducted with only one strain of HIV-1, and the earliest time point
evaluated was 7 days p.i. Earlier time points and interaction of
other HIV-1 and HCMV strains remain to be examined. It
should be noted, however, that similar results were obtained
with both cell-associated HCMV strains and the cell-free strain
CMVPT30-gfp.
Cytokine production
Infection by either HCMVor HIV-1 has been associated with
the upregulation of proinflammatory cytokines (Craigen et al.,
1997; Grundy et al., 1998; Humar et al., 1999; Lane et al.,
2001a; Lane et al., 2001b; Lurain et al., 2004; Murayama et al.,
1994; Oguariri et al., 2007; Redman et al., 2002). Therefore, the
release of cytokines from the explants into the supernatant fluid
in response to HCMV and HIV-1 infection was analyzed.
IL-6, IL-8, IL-1β, interferon (IFN)-α, IFN-β, IFN-γ, and
GRO-α were assayed at days 7, 14, and 21 p.i. in the
supernatants from explants infected with either HCMVor HIV-1
or co-infected with HCMV and HIV-1. IFN-α, IFN-β, IFN-γ,
and IL-1β were not detected in any of the supernatant samples.
At day 14 p.i., tissues infected with one or both viruses showed
increased levels of IL-6, IL-8, and GRO-α compared to un-
infected control tissues (Fig. 5). The pattern of increase under
each condition (single or dual infection) was similar for each of
the three cytokines.
Phenotype of HCMV-infected cells
The next question we wanted to address was the identity of
the specific cell type(s) in the explants that are infected with
HCMV. The size and morphology of the fluorescent cells in-Fig. 5. Cytokine concentrations in explant supernatant fluid from two singly
infected or co-infected tissues. Solid bar ( ): uninfected control tissue;
Cross-hatch bar ( ): CMVPT30-gfp; Vertical bar ( ): HIV-1Ba-L;
Diagonal bar ( ): CMVPT30-gfp/HIV-1Ba-L co-infection. Supernatants were
collected at 14 days p.i.
anti-mouse secondary ab. Images taken with a SPOT RT KE 7.3 Three Shot
Color digital camera.fected with CMVPT30-gfp (Fig. 1A) suggested they could be
macrophages, dendritic, or Langerhans cells. The first approach
to identify the infected cells was to analyze frozen sections of
HCMV-infected tissues. The sections were stained with mouse
anti-human CD68, anti-HLA-DR, or anti-CD1a primary mAbs
followed by an Alexa Fluor 594-conjugated rabbit F(ab′)2 anti-
mouse IgG secondary Ab. In explants infected with the clinical
strain NW23-3, there were cells that were positive for HCMV
p52, and either CD68 (Figs. 6A–D) or HLA-DR (data not
shown).
The tissues in which NW23-3-specific antigens were
detected had been in culture for 14–21 days. No CD1a-positive
cells in either infected or uninfected control explants could be
detected at this time point. However, the anti-CD1a antibody
(hybridoma supernatant) detected Langerhans-like cells in
uninfected tissues, which were sectioned after only 3 days in
61A.M. Fox-Canale et al. / Virology 369 (2007) 55–68culture (Fig. 6E). Similar results were obtained for uninfected
cells using an anti-CD207 (langerin) antibody (data not shown)
indicating that these are Langerhans cells.
The second approach to identify the cells infected with
HCMV was to dissociate tissues with collagenase and analyze
the released cells using flow cytometry. The positive/negative
cutoff (gate) was determined for GFP-positive cells based on
analysis of uninfected control tissues (Figs. 7A–C) and
CMVPT30-gfp-infected fibroblasts (data not shown). The
same population was identified by gating on CD45-positive
cells, indicating that the infected cells are leukocytes rather than
stromal or epithelial cells. CD68 was also expressed on the
GFP-positive population, which is consistent with the immu-
nohistochemical analysis described above. Anti-CD68 and anti-
CD14 antibodies identified the same cell population (data not
shown), therefore anti-CD14 was used in all subsequent ana-
lyses. All GFP-positive cells were analyzed for expression of
CD14, CD1a, and HLA-DR. The consensus phenotype of these
infected cells is CD45+/CD14+/CD1a+/HLA-DR+ (Figs. 7E
and F). Isotype-matched controls for all antibodies were nega-
tive (data not shown).
Co-infection of cells
The fact that both HCMV and HIV-1 were detected at the
same time in infected explants suggested that there could be co-
infection of the same cell. As a first step to demonstrate that co-
infection was possible, monocyte-derived macrophages, which
are known to be permissive for HCMV (Bego and St Jeor,
2006), were inoculated with CMVPT30-gfp for 72 h followedFig. 7. Flow cytometric analysis of dissociated cells from CMVPT30-gfp-infected tis
uninfected cells: CD14 versus HLA-DR; (C) Dot plot of uninfected cells: CD14 versu
gfp-infected tissues; (E) Dot plot of CD14 versus HLA-DR surface expression on CM
on CMVPT30-gfp-infected cells.by infection with HIV-1Ba-L. After an additional 48 h, appro-
ximately 10% of the cells expressed GFP and 10% of those were
found to express both GFP and p24 antigen (Fig. 8A).
To determine whether co-infection occurs in the cervical
explants, frozen sections of tissues infected with both viruses
were examined for co-localization of GFP and p17/p24 antigen.
Fig. 8B shows a tissue section in which there are cells singly
infected with HCMVor HIV-1 as indicated by the white arrows.
The cell outlined in the section is enlarged in the images to the
right showing the individual fluors. Both GFP and p17/p24
antigens are expressed indicating co-infection.
Sequences of HCMV UL128–131 open reading frames (ORFs)
The immunofluorescence and flow cytometry data indicated
that CMVPT30-gfp infects Langerhans-like cells in the tissue
explants. Recent work has shown that the three HCMV ORFs,
UL128, UL130 or UL131, determine HCMV tropism, which
can be altered by deletion or mutation of any one of the 3 ORFs
(Hahn et al., 2004; Jarvis and Nelson, 2006; Patrone et al., 2005;
Ryckman et al., 2006; Wang and Shenk, 2005). Therefore, we
sequenced the stocks of CMVPT30-gfp, NW23-3, CH-14, and
CH-22 for the presence of mutations affecting expression of
these ORFs. No mutations were found in UL130 or UL131 in
any of these stocks, and no mutations were found in the UL128
ORF from the stocks of the three clinical strains (Table 2). The
supernatant and tissue extracts infected with the three clinical
strains also showed no mutations in any of the three genes.
However, in CMVPT30-gfp, a mutation was found in the splice
donor AG dinucleotide of the first intron of UL128. The specificsues. (A) Histogram of dissociated cells from uninfected tissues; (B) Dot plot of
s CD1a; (D) Histogram of GFP expression of dissociated cells from CMVPT30-
VPT30-gfp-infected cells; (F) Dot plot of CD14 versus CD1a surface expression
Fig. 8. (A) HCMVand HIV-1 co-infection of macrophages in cell culture. Panels at the left, top to bottom, show DAPI stain of nuclei; HCMV GFP expression; and
anti-HIV-1 p24/p17 ab binding detected by Alexa fluor 594-conjugated F(ab′)2 rabbit anti-mouse secondary ab. Large figure shows the merge of all 3 fluors. Single
frame of a deconvolved z-stack shown. (B) HCMVand HIV-1 co-infection of cells in tissue. Cell outlined in large figure is shown enlarged at the right. Top to bottom:
HCMV GFP fluorescence; HIV-1 p17/p24 detected by specific primary monoclonal antibodies and Cy5-conjugated secondary ab; merge of GFP and Cy5 with DAPI
stain of nuclei. Single frame of a deconvolved z-stack shown. White arrows indicate singly infected cells: HCMV (green), HIV-1 (red).
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predicted result would be read-through into the intron leading to
an in-frame stop codon in the intron sequence, which would
prematurely terminate the expressed protein four amino acids
downstream of the end of the product encoded by the first
exon. The same mutation in the UL128 splice donor site was
found in CMVPT30-gfp isolated from infected tissue and
culture supernatant fluid, but no additional mutations were
found in any of the three genes. Despite the UL128 mutation,
CMVPT30-gfp replicated to high copy numbers in the tissue
explants, and infectious virus was released into the culture
medium.
Discussion
The limitations of cell culture and animal models for the
study of HCMV pathogenesis prompted the development of a
cervical explant model that is permissive for HCMV infection
and also supports HIV-1 co-infection. Two cervical explant
models have been described for HIV-1 (Collins et al., 2000;
Greenhead et al., 2000). One reported by Collins et al. (2000)
uses polarized 6 mm punch biopsies in Transwells surrounded
by agarose with only the epithelial surface exposed to the
inoculum. This model was developed for studies of virus entry
and transit across the epithelial layer; however, it is technicallyTable 2
Mutations in HCMV ORFs UL128, UL130, and UL131A
HCMV strain Sample type Mutations UL128–131A
CMVPT30-gfp Stock Splice donor AG UL128
Explant supernatant Splice donor AG UL128
Explant tissue Splice donor AG UL128
CH-14/CH-22/NW23-3
(clinical strains)
Stock Wild type
Explant supernatant Wild type
Explant tissue Wild typedifficult to prevent leakage around the sides of the tissue. We
found these punch biopsies to be permissive for HCMV
infection (data not shown). However, at most 10 to 12 explants
could be obtained from the same cervical specimen, and the
maximum viability of the explants was approximately 7 days.
This is too short a time period to adequately study HCMV
infection and replication, which takes up to 2 weeks or longer to
reach peak titers. The second model described for HIV-1
(Fletcher et al., 2005; Hu et al., 2004) uses small tissue blocks
that retain an epithelial surface. The tissues are inoculated and
maintained submerged in medium, which allows exposure of all
surfaces to the inoculum. The advantages of this model are that
the virus can access multiple cell types, and a large number of
tissue samples can be obtained from the same specimen allow-
ing comparative analyses of different experimental conditions.
The primary focus of our experiments was to examine repli-
cation of HCMV in all potentially permissive cells and to study
co-infection with HIV-1. For these reasons, we adapted and
further developed the second explant model for HCMV infect-
ion. Importantly, the tissues remain viable up to 28 days, which
allows sufficient time to achieve peak levels of HCMV
replication. To our knowledge, this is the first study to use an
ex vivo model for HCMV infection of tissue derived from the
female genital tract, a compartment in which this virus is
actively shed.
The recombinant HCMV strain CMVPT30-gfp was chosen
for the initial development of the model to provide visual con-
firmation of infection. The number of GFP-expressing fluor-
escent cells increased over the period of culture in the cervical
tissue, which indicated permissive replication. A more quanti-
tative measure of replication was obtained by real-time PCR,
which showed that the peak copy numbers of HCMV DNA
usually occurred at 14–21 days p.i. However, it was evident
from the comparison of results from multiple experiments using
specimens from different hosts that there is considerable
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tissue extracts. This emphasizes the fact that comparative stu-
dies of the effects of virus replication need to be carried out in
tissue derived from the same host to minimize the variability.
There is an additional caveat associated with the use of
CMVPT30-gfp to study HCMV infection in cervical tissue
explants, namely that CMVPT30-gfp is phenotypically different
from true low-passage clinical strains. CMVPT30-gfp produces
extracellular virus, while clinical strains are completely cell-
associated in monolayer cell cultures. To determine the rele-
vance of the growth characteristics of CMVPT30-gfp observed
in tissue explants, cell-associated clinical isolates of HCMV
were also tested for infectivity in this same model. Although
there was no way visually to follow the infectivity of the clinical
isolates, quantitation of viral DNA extracted from the tissues
demonstrated increased DNA copy numbers, which peaked at
14–21 days post-infection. In some experiments in which both
CMVPT30 and clinical isolates were compared in the same
tissue, the peak copy numbers for the clinical isolates were up to
1.5 log higher than those for CMVPT30-gfp (Fig. 2C). This
suggests that at least some cell-associated strains might be better
adapted than the cell-free strain for infection of the explants.
HCMV copy numbers were decreased by foscarnet in a dose-
dependent manner. Therefore, it was possible to determine the
effect of an antiviral agent with specific activity against HCMV,
which further confirmed that HCMV actively replicates in the
explants. In addition, this suggests that the model, which has
been used for HIV-1 microbicide testing (Fletcher et al., 2005;
Fletcher et al., 2006; Greenhead et al., 2000; Hu et al., 2004),
could be used for similar testing of potential anti-HCMVagents.
In contrast to HCMV, there was much less variability in HIV-1
infectivity as measured by p24 antigen, which reached peak
levels earlier (at 7 days p.i.) compared to HCMV. To rule out the
persistence of p24 antigen associated with the inoculum,
infectivity was confirmed by the qualitative detection of HIV-1
DNA in all tissues with p24 antigen-positive supernatants.
The HIV-1Ba-L strain was used in our studies, because R5 strains
have been most often associated with sexual transmission, and it
was shown by others to replicate well in explant tissue (Feng et
al., 2003). In our model, HIV-1Ba-L infection did not require
PHA-stimulation. Others have reported similar findings for R5
viruses, while X4 and dual tropic HIV-1 strains did require
PHA-stimulation for infection of cervical explant tissues
(Greenhead et al., 2000; Hu et al., 2004). Additional evidence
from other studies suggests that HIV-1 can infect multiple cell
types in the female genital tract (Howell et al., 1997; Yeaman
et al., 2004).
Having established the ability of both viruses to infect and
replicate in the explants, we investigated the tissue response to
the infection. The rationale for this approach was that the in-
flammatory state of the tissue at the time the specimen is taken
has been shown to affect HIV-1 infectivity (Maher et al., 2005;
Patterson et al., 1998; Sturm-Ramirez et al., 2000). Upregula-
tion of the pro-inflammatory cytokines IL-6, IL-8, and GRO-α
reportedly occurs in response to infection by HIV-1 and HCMV
in cell culture (Craigen et al., 1997; Grundy et al., 1998; Humar
et al., 1999; Lane et al., 2001a, 2001b; Murayama et al., 1994;Redman et al., 2002). At 7 and 14 days post-infection, which
were the two time points tested, infected and co-infected tissues
produced higher levels of IL-6, IL-8, and GRO-α compared to
uninfected control tissues (Fig. 4). The higher results obtained
with co-infected tissues may reflect additive effects of repli-
cation by both viruses. Interferons α, β, and γ were not detect-
ed, but it is possible that differential effects of single infection
and co-infection on these cytokines occur before 7 days.
It was previously reported that HIV-1 infects macrophages
and CD4+ T cells in cervical explants (Collins et al., 2000;
Greenhead et al., 2000). We wanted to determine the target
cell(s) for HCMV, which has been reported to infect a wide
range of cell types in vivo including fibroblasts, epithelial cells,
endothelial cells, smooth muscle cells, macrophages, and
dendritic cells (Gerna et al., 2005; Hahn et al., 2004; Hertel et
al., 2003; Sinzger et al., 1995). The size and morphology of the
cells that expressed GFP in CMVPT30-gfp-infected tissues
suggested that the target could be a macrophage, dendritic cell,
or Langerhans cell (Fig. 1). Our results from immunohisto-
chemical analysis of frozen sections indicated that CD68, a
marker of monocyte–macrophage lineage (da Costa et al.,
2005), and HLA-DR are expressed on the HCMV-infected cells,
but CD1a was not detected on these same cells.
CD1a-positive cells morphologically resembling Langer-
hans cells were detected in uninfected tissues at 3 days p.i. but
not at 14 days p.i. It is likely that uninfected Langerhans cells
would have migrated from the tissues after 14 days, but cells
expressing GFP do not appear to leave the tissue during the
period of culture. The failure to detect CD1a expression on
infected cells in these sections compared to detection by flow
cytometry (see below) may reflect potential differences in CD1a
expression over time and lower sensitivity of the anti-CD1a
hybridoma supernatant used for detection in the sections.
HIV-1 infection of cervical explants has been reported by
others to target cells that express CD68, which were described
as subepithelial macrophages. No CD1a+ cells were found to
express p24 antigen (Greenhead et al., 2000).
For further determination of the HCMV-infected cell phe-
notype in the explants, cells dissociated from tissues were ana-
lyzed by flow cytometry. There was no evidence that stromal,
epithelial, or endothelial cells were infected. This was sur-
prising, because extracellular strains of HCMV only grow in
vitro in normal diploid fibroblasts, and low-passage clinical
isolates grow in both fibroblasts and endothelial cells. The
GFP+ cell population was also CD45+ indicating that the
infected cells were leukocytes. CD68 and CD14 were both
expressed by the GFP+ cell population. The consensus
phenotype of the GFP+ cells was found to be CD45+/CD1a+/
CD14+/HLA-DR+. Although the morphology of the cells as
seen in Fig. 1 resembles macrophages, dendritic, or Langerhans
cells, this phenotype is not strictly consistent with any of these
cell types. Macrophages would be predicted to be CD14+/
CD1a−, and dendritic cells and Langerhans cells are usually
CD14−/CD1a+. However, antigen presenting cells that are
CD14/CD1a double positive have been reported under both
normal and disease conditions such as Langerhans cell his-
tiocytosis. The double-positive cells may represent a subset of
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Caux et al., 1992; Geissmann et al., 2002; Geissmann et al.,
2001; Paczesny et al., 2007). Regardless of the actual cell
identity, CMVPT30-gfp appears to infect a migratory cell,
which is not necessarily uniformly distributed throughout the
tissue sample. Others have observed a wide variability in the
number of dendritic and Langerhans cells in the normal uterine
cervix (Poppe et al., 1998), which could partially explain the
intra-tissue variability in HCMV copy numbers that we have
observed.
Infection of both HCMVand HIV-1 in the same tissue allows
for the possibility of co-infection of the same cell. Recent
reports have described HCMV and HIV-1 interaction in mono-
cyte-derived macrophages. King et al. (2006) have shown in
cultures of myeloid cells and primary macrophages that HCMV-
infected cells upregulate CCR5 expression on uninfected
bystander cells, which then have enhanced susceptibility to
HIV-1. At the same time, CCR5 expression was decreased for
HCMV-infected monocyte-derived macrophages. However,
rare cells expressed both HCMV immediate-early antigens
and HIV-1 Gag. Maheshwari et al. (2006) also reported infre-
quent observations of both HIV-1 and HCMV antigens in
monocyte-derived macrophages in culture as well as in cells in
the intestinal mucosa of co-infected patients. Our immunohis-
tochemical analysis of macrophage cultures definitively showed
expression of both GFP and the HIV-1-specific antigens p17/
p24 (Fig. 8A). The observation of co-infection of the same cell
in culture was corroborated in frozen sections of infected ex-
plants, in which occasional cells were found to express both
GFP and p17/p24 (Figs. 8A and B). How these viruses interact
within the same cell remains to be determined.
HCMV cell tropism has been linked to the HCMV ORFs
UL128, UL130, or UL131A. Mutations, which can appear in
any of these 3 ORFs after short passage in vitro, may produce
altered cell tropism (Gerna et al., 2005; Hahn et al., 2004; Jarvis
and Nelson, 2006; Patrone et al., 2005; Ryckman et al., 2006;
Wang and Shenk, 2005). CMVPT30-gfp, NW23-3, CH-14, and
CH-22 DNA extracted from viral stocks, infected tissue, and
culture supernatants were sequenced in the region UL128 to
UL131 to check for mutations. The stocks of the three clinical
strains, CH-14, CH-22, and NW23-3, contain no mutations in
any of the three ORFs. The CMVPT30-gfp strain was found to
carry a mutation in a splice-junction dinucleotide in UL128 but
no mutations in UL130 or UL131. Despite the mutation in
CMVPT30-gfp, it appears to replicate to high copy numbers in
infected tissues. The question remains, however, whether the
mutation influences the tropism for the cell phenotype that we
have observed. It also remains to be determined whether strains
with mutations in the other two ORFs will have altered infect-
ivity in the cervical explant tissue. The explants provide a
human tissue model to study HCMV strains with mutations in
this region, which should allow individual mutations to be
linked with specific cell-tropism phenotypes.
Beyond analysis of cell tropism, the model could be used for
characterization of HCMV infection at the level of gene
expression. Recently it was reported that the pattern of rat
CMV gene expression varies in vivo in different tissues (Streb-low et al., 2007). Approximately 95% of the known ORFs were
expressed in vitro in different cell types, while in vivo the
pattern of expression varied with the type of tissue infected and
tended to be restricted to genes that encode products involved
in immune evasion rather than viral replication. These findings
for rat CMV demonstrate that viral gene expression in cell
culture monolayers may not accurately reflect gene expression
in vivo. An ex vivo tissue model could be used to determine
whether HCMV infection undergoes similar restriction of gene
expression.
The importance of the cervical explant model that we have
developed is the ability to study the pathogenicity of human
viruses, such as HCMV and HIV-1, within the natural archi-
tecture of human tissue, which contains multiple cell types. We
have shown that cervical tissue is permissive for infection by
cell-free and cell-associated HCMV strains and co-infection by
an HIV-1 macrophage-tropic (R5) strain. The results of our
quantitative co-infection studies, although not yet definitive,
suggest that HIV-1 may enhance HCMV infection. To gain a
broader understanding of HCMV and HIV-1 interaction in the
female genital compartment, co-infection with other R5 strains
as well as CXCR4 and dual-tropic strains needs to be examined.
Using this model, it will be possible to: (1) identify the specific
types of infected cells; (2) analyze virus genotype in relation-
ship to cell tropism; (3) determine the tissue and virus response
to infection; and (4) evaluate the effects of antiviral agents and
microbicides. Thus, these explants provide a relevant “in vivo-
like” model to study infection and interaction of HCMV and
HIV-1 in the female genital tract.
Materials and methods
Virus strains
A recombinant extracellular HCMV strain was constructed
from a low-passage HCMV clinical isolate PT30 (Lurain et al.,
1999) and the green fluorescent protein (GFP) expression
plasmid MP234 derived from the vector pIRES-hrGFP1a
(Stratagene, La Jolla, CA) (a gift from Mark Peeples, Ohio
State University, Columbus, OH). The recombinant strain
CMVPT30-gfp expresses the humanized Renilla GFP under the
control of the CMV major immediate early promoter and pro-
duces extracellular virus. CMVPT30-gfp replicates to similar
titers (approximately 1×106) and with the same growth kinetics
as the parental strain PT30 (Lurain et al., 1999). There was no
deletion of any of the open reading frames UL133 through
UL148, which are conserved in all clinical isolates but are
deleted in some higher passage laboratory strains (Cha et al.,
1996).
The HCMV clinical strains NW23-2, CH-14, and CH-22
(Lurain et al., 2006) were obtained from patient isolates at
Loyola University Medical Center, Maywood, IL through an
Institutional Review Board (IRB)-approved protocol. All HCMV
strains were propagated in human foreskin fibroblasts (HFF)
(Viromed, Minneapolis, MN) in Eagle's minimum essential
medium (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum, 20 mM HEPES buffer, 2 mM L-glutamine,
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clinical strains were maintained as cell-associated virus and
were passaged three to five times in HFF. Infected HFF to be
used as a source of virus for infection of tissue were harvested at
approximately 80% CPE, frozen at −80 C, and transferred to
liquid nitrogen for storage. The HIV-1Ba-L strain (R5) was
obtained through the NIH Division of AIDS Viral Quality
Assurance Laboratory at Rush University Medical Center,
Chicago, IL.
Tissue samples
Ectocervical tissue samples from premenopausal women
undergoing hysterectomies for benign disease were obtained
with patient consent at Northwestern University Prentice
Women's Hospital, Chicago, IL. The tissues were placed
immediately in medium containing 2.5 μg/ml amphotericin B
(Invitrogen), and transferred without identifiers within 4 h after
surgery for processing in the laboratory at Rush University
Medical Center. The experimental protocol was approved by the
IRB at both institutions.
The tissues were washed in an antibiotic solution containing
Dulbecco's phosphate-buffered saline (Invitrogen), supplemen-
ted with penicillin–streptomycin 200 units–200 μg/ml, nystatin
500 units/ml, amphotericin B 5 μg/ml, and gentamicin 100 μg/
ml. The tissue was subsequently washed three times in RAFT
medium: Dulbecco's minimal essential medium (Invitrogen)
containing 24% Ham's F12 nutrient mixture, 10% fetal bovine
serum, 20 mM HEPES buffer, penicillin–streptomycin
100 units–100 μg/ml, insulin 5 μg/ml, gentamicin 50 μg/ml,
and 1 mM sodium pyruvate. The tissues were cut into appro-
ximately 3 mm3 (10–60 mg) blocks, which retained the epithe-
lial surface. Three explants were placed into individual wells of
a 48-well tissue culture plate that contained 500 μl RAFT
medium. Explants for HCMV infection were inoculated im-
mediately with either a cell-associated clinical HCMV strain
(approximately 5×103 infected cells per well) or the cell-free
CMVPT30-gfp strain (1×105 pfu/well) and maintained com-
pletely submerged in the inoculum-containing medium. The
HCMV inoculum was removed after 72 h. Tissues were washed
twice in RPMI (Invitrogen) without FBS. At this time all
explants for HIV-1 infection were inoculated with HIV-1Ba-L
(3.0×104 TCID50 per well). The HIV-1 inoculum was removed
after an additional 72 h. The explants were washed vigorously
two times in RPMI medium, transferred to fresh RAFT medium
in new 48-well plates, and cultured up to 28 days p.i. with
complete changes of medium every 2 to 3 days.
MTT assay
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assays were performed to monitor viability (Fletcher
et al., 2006). Single explants were added to individual wells of a
48-well plate containing 500 μg/ml of MTT in Dulbecco's mi-
nimal essential medium (Invitrogen). The explants were incu-
bated at 37 °C for 3 h and then transferred to new 48-well plates
containing 1 ml methanol per well. The plates were incubatedand rotated at room temperature overnight in the dark. For
analysis, explants were removed to preweighed tubes to record
the weight. The absorbance of 3 replicates of the MTT super-
natant fluid was determined at 570 nm on a CERES 900 UV
HDi plate reader (Bio-Tek Instruments, Winooski, VT).
DNA extraction
HCMV DNA from infected explants was extracted with the
QIAamp DNAMini Kit (Qiagen, Valencia, CA) using the tissue
protocol. Before extraction, individual tissues were weighed,
cut into smaller pieces, and lysed using the buffer provided.
Volumes after lysis were approximately 200 μl. The QIAamp
DNA Mini Kit was also used to extract HCMV DNA from
200 μl of tissue culture supernatants using the Blood and Body
Fluid Spin Protocol. All samples were eluted in a final volume
of 100 μl.
Replication of CMVPT30-gfp and HCMV clinical strains
Infected explants were monitored for GFP-expressing cells
by fluorescence microscopy daily until termination of the expe-
riment. Values of 1+ through 5+ were used to score the number
of fluorescent cells (1+, 1–20 cells; 2+, 21–50 cells; 3+, 51–
100 cells; 4+, 101–200 cells; 5+, N200 cells).
HCMV replication was measured quantitatively by real-time
PCR using an in-house assay and the Applied Biosystems 7500
Real-Time PCR System (Applied Biosystems, Foster City, CA).
The primer pair, forward (5′-CTCGTGCGTGTGCTACGAGA-
5′) and reverse (5′-GCCGATCGTRAAGAGATGAAGAC-5′)
was used to amplify a 132 kb product from the conserved N-
terminus of the DNA polymerase gene, which was detected with
the probe 5′-6FAM-AGTGCAGCCCCGRCCATCGTTC-
TAMRA-5′. The reaction was performed in a total volume of
25 μl, using Taqman 2× Universal master mix (Applied Biosys-
tems). Amplification consisted of one cycle of 50 °C for 2 min,
and 95 °C for 10 min; and 50 cycles of 95 °C for 15 s, and 60 °C
for 1 min. Dilutions of HCMV DNA of known copy number
(Advanced Biotechnologies Inc., Columbia, MD) were used to
generate a standard curve. Analysis was performed using the
Applied Biosystems 7500 System Sequence Detection Software
version 1.3. HCMV DNA copy number was normalized to the
tissue weight recorded before the DNA extraction.
HIV-1Ba-L detection and quantitation
For HIV-1Ba-L quantitation studies, the inoculum was re-
moved from the explants at day 3 p.i. The explants were
washed 3 times with serum-free RPMI, and transferred to new
plates. Samples of supernatant fluid were taken at this time
point for p24 antigen quantitation to determine the residual
inoculum background. Additional samples were quantitated at
7, 14, and 21 days p.i. The Alliance HIV-1 p24 Antigen ELISA
kit (PerkinElmer, Wellesley, MA) was used for quantitation. All
supernatants were diluted 1:8 to obtain readings within the
linear range of the assay. Samples with values above this range
were further diluted and re-tested. The p24 antigen data were
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(LDMS) (Frontier Science and Technology Research Founda-
tion, Inc., Amherst, NY). HIV-1 DNA was extracted from the
tissues using the QIAamp DNA Mini Kit (QIAGEN), and
detected using the AMPLICOR HIV-1 DNA test, version 1.5
(Roche Molecular Systems, Inc., Branchburg, NJ), which gives
only qualitative results.
Foscarnet inhibition assay
In a 48-well plate, four replicate wells each containing three
tissue blocks, were pretreated with foscarnet concentrations
ranging from 50 μM to 800 μM for 72 h. After the prein-
cubation period, the drug-containing medium was changed and
the tissues were inoculated with CMVPT30-gfp as previously
described. Thereafter, medium with drug was completely re-
placed twice per week. HCMV DNA was quantitated by real-
time PCR at day 14 p.i.
Cytokine analysis
Supernatants were collected and assessed for various cyto-
kines at 7, 14, and 21 days p.i. Human IL-6, IL-8, IL-1β, IFN-α,
IFN-β, and IFN-γ were assayed using ELISA kits (Invitrogen),
and human GRO-α was determined by the Quantikine
Immunoassay for Human CXCL1/GRO-α (R&D Systems,
Minneapolis, MN). Standard curves were constructed based on
the optical density of the standards provided with each kit.
Samples producing signals greater than the highest standard
were further diluted using the standard diluent buffer provided
and were reanalyzed. The ELISA plates were read at 450 nm on
a DuPont Kinetic Microplate Reader (Molecular Devices,
Sunnyvale, CA).
Immunofluorescence
Tissue specimens for immunofluorescence staining were
placed in OCT medium (Ted Pella, Redding, CA) or Neg50
(Richard Allan Scientific, Kalamazoo, MI), immediately frozen,
and stored at −80 °C. Ten micron sections were made using a
Microm HM550 cryostat (Richard Allan Scientific). Sections
were fixed in PIPES buffer solution containing 3.7% formalde-
hyde, 2 mM MgCl2, 1 mM EGTA, and 100 mM PIPES. Slides
were washed between incubation steps four times in Dulbecco's
phosphate-buffered saline at 4 °C (Invitrogen). Sections were
blocked using 20% (v/v) rabbit serum (Sigma-Aldrich, St.
Louis, MO) containing 0.1% Triton X-100 and 0.01% Sodium
Azide (Sigma-Aldrich). Unconjugated mouse anti-human
CD68 or HLA-DR (Invitrogen) monoclonal antibodies (mAb)
were added to tissue sections from cervical tissue that had been
infected with either CMVPT30-gfp or HCMV cell-associated
clinical strains. A mouse anti-human CD1a hybridoma super-
natant (OKT6) was also used as a primary antibody. Alexa-fluor
594 F(ab′)2 rabbit anti-mouse IgG (Invitrogen) and Cy5-
conjugated donkey anti-mouse whole IgG (Jackson ImmunoR-
esearch, West Grove, PA) were used as secondary antibodies.
Nuclei were visualized using Slow-Fade Gold Antifade reagentwith DAPI (4′,6-diamidino-2-phenylindole; Invitrogen). Tis-
sues that had been infected with the cell-associated clinical
strains were directly stained for the delayed early DNA binding
protein, p52, using a mouse FITC-conjugated anti-cytomega-
lovirus mAb, Clone CCH2 (Dako, Glostrup, Denmark). HIV-1
infection in tissues was detected using mAb p17 (Capricorn,
Portland, ME) and p24 (AG 3.0, NIH AIDS Research and
Reference Reagent Program). Slides were imaged with a Delta-
Vision RT epifluorescent microscope (Applied Precision Inc.,
Issaquah, WA). Images were captured as z-series on a CCD
digital camera. Out of focus light was digitally removed using
the Softworks deconvolution software (Applied Precision Inc.).
Alternatively slides were imaged with a Nikon eclipse TE 2000-
S inverted fluorescence microscope equipped with a SPOT RT
KE 7.3 Three Shot Color camera (Diagnostic Instruments, Inc,
Sterling Heights, MI) using MetaMorph version 6.0 imaging
software (Molecular Devices Corp.).
Flow cytometry
Cells were dissociated from intact tissues for flow cytometric
analysis (Baig et al., 2002). Approximately 12 explant tissues
were collected in 10 ml complete RPMI with 5% FBS (RPMI-
5). The tissues were pelleted at 400×g, resuspended in 30 ml 1×
Hanks Balanced Salt Solution (Invitrogen) with 5% FBS and
0.5 mM EDTA and rotated at 300 RPM at 37 °C in a Model G25
Controlled Environmental Incubator Shaker (New Brunswick
Scientific Company, Inc., Edison, NJ) at 37 °C to loosen the
epithelium. The tissues were pelleted again and resuspended in
RPMI-5 containing 60 units/ml Type II Collagenase (Sigma-
Aldrich) and rotated for 1 h at 37 °C. The tissues were pelleted,
resuspended in 10 ml RPMI-5, and passed approximately 10
times through a 20 cm3 syringe with a 16 gauge feeding needle
to dissociate the cells. The cell suspension was passed through a
Falcon 70 μm cell strainer (BD Biosciences, San Jose, CA). The
filtered suspension was pelleted and resuspended in 10 ml
RPMI-5. The suspension was layered over a 35%–65% discon-
tinuous Percoll (Sigma-Aldrich) gradient and centrifuged for
20 min at 1000×g. Cells were collected from above the 35%
layer as well as from the interface between the 35% and 65%
layers, washed and resuspended in RPMI-5. Approximately
1×106 dissociated cells were obtained from up to 12 explants
from the same specimen.
Cells were treated with FcR Blocking Reagent (Miltenyi
Biotec, Auburn, CA) and stained with fluorochrome-conjugated
mouse anti-human mAbs at room temperature for 20 min in the
dark. The anti-CD14-PerCP (peridinin-chlorophyll-protein),
anti-CD45-APC (allophycocyanin), and anti-HLA-DR-PE-
Cy7 (phycoerythrin-cyanin7) mAb were obtained from BD
Biosciences; and anti-CD1a-PE was obtained from Beckman
Coulter (Miami, FL). Isotype-matched control antibodies were
used as negative controls. Following incubation, the cells were
washed twice with cold PBS containing BSA, fixed with 2%
formaldehyde, and stored at 4 °C until analysis. Samples were
acquired and analyzed on a BD LSR II flow cytometer using
FACSDiva v5.01 software (BD Biosciences). GFP was ana-
lyzed in the FL1 channel. The gate for GFP+ cells was
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fected control tissues and GFP fluorescence in CMVPT30-gfp-
infected fibroblasts.
Sequencing HCMV open reading frames (ORF) UL128,
UL130, and UL131
The genomic region containing HCMV ORFs UL128-
UL131 was amplified from DNA extracts of virus stocks,
supernatant fluid, and infected tissue as a 2275 bp product using
the following primers 5′-CTCTATCGGCGATAAACACC-5′
(forward) and AACTGACCACCTCGGAAATG-5′ (reverse).
The complete product was sequenced and sequences were com-
pared to those of the HCMV strains Merlin (GenBank accession
number AY446894) and AD169 (GenBank accession number
NC001347) to identify mutations that affect predicted protein
expression.
Statistical analysis
Real-time PCR quantitative results were compared using the
Wilcoxan rank sum test.
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